Dermatomyositis (DM) is a rare, autoimmune muscle and skin disease that can also affect the heart, lungs, and other organs of the body.
DM is one of several types of the Idiopathic Inflammatory Myopathies. The term “idiopathic” means no known cause.
Adult Dermatomyositis Externally-Led Patient-Focused Drug Development Meeting: Community Orientation Webinar
, , Dermatomyositis, Featured, News
MSU and TMA are leading the first-ever Adult Dermatomyositis Externally-Led Patient-Focused Drug Development (EL-PFDD) meeting on June 7, 2024....
Priovant Therapeutics joins MSU to discuss The Valor Study for Dermatomyositis, a phase 3 clinical trial for Adult Dermatomyositis....
IVIg Proves Effective for Dermatomyositis in Phase 3 Trial
, , Dermatomyositis, Featured, Myositis Treatments
The study provided efficacy data for Octagam 10%, which was approved for dermatomyositis by the US Food and Drug...
The VALOR Study – New Clinical Research Opportunity for Dermatomyositis
, , Dermatomyositis, Featured, Video
We hosted Priovant Therapeutics to discuss The Valor Study, a phase 3 clinical trial for adult dermatomyositis. Learn all...
Dermatomyositis and Sun Protection, Dr. Graham makes it clear the sun can cause flares. She talks about sunscreens and...
Dr. Graham educates about the skin manifestations of myositis, sharing the various DM rashes, cosmetic cover-ups, information and tips...
The Power of Our Voice: FDA Listening Session for Adult DM Webinar
, , Dermatomyositis, Featured, News, Video
Watch the recording of our fireside chat, The Power of Our Voice: FDA Listening Session for Adult Dermatomyositis, where...
View the summary of our first-ever FDA Listening Session on Adult Dermatomyositis. This was an opportunity to facilitate the...
Watch the recording with Alexion Pharmaceuticals to learn about the Flex Study to evaluate the safety and efficacy of...
Seeking ten (10) people living with Dermatomyositis who would be willing to share their personal experience in a market...
Myositis Support & Understanding and AllStripes Partner for New Dermatomyositis Research
, , Dermatomyositis, Featured, Research
Myositis Support & Understanding and AllStripes are partnering to create a database that will enable new Dermatomyositis research projects!...
Corbus Pharmaceuticals Announces Topline Results from DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
, , Dermatomyositis, Featured, Research
Corbus releases topline results for the phase 3 study of lenabasum in dermatomyositis. While it didn't meet the primary...
A Closer Look: Clinical Trials and the PRESIDIO Study
, , Dermatomyositis, Featured, Necrotizing Autoimmune Myopathy, Polymyositis, Video
Clinical trials are a key research tool for advancing medical knowledge and patient care. Join Kezar Life Sciences as...
Skin findings seen with myositis autoantibodies and treatment of skin in dermatomyositis
, , Dermatomyositis, Featured, News, Video
Dr. Victoria Werth joined us live online for a video education session titled, "Skin findings seen with myositis autoantibodies...
DETERMINE - a Phase 3 trial designed to evaluate the efficacy and safety of lenabasum for the treatment of adults...
Corbus launches DETERMINE, a Phase 3 trial of lenabasum for the treatment of dermatomyositis
, , Dermatomyositis, Featured, News
New locations announced July 9, 2019. DETERMINE is a double-blind, placebo-controlled 1-year study designed to test the efficacy and...
Myositis and Cancer: Risk highest for carriers of anti-TIF1 antibody
, , Dermatomyositis, Featured, News
The research found that DM patients with the anti-transcriptional intermediary factor 1 (anti-TIF1) antibody were more than three times...
"New Developments on the Role of Itch in Dermatomyositis", based on new research published in the British Journal of...
Dr. Victoria Werth, MD, presents, "Overview and new developments in Dermatomyositis." This was a live Myositis Support and Understanding...
